SyntekaBio Inc Cash Flow-to-Debt Ratio
SyntekaBio Inc cash flow-to-debt ratio. SyntekaBio Inc (226330) has a Cash Flow-to-Debt Ratio of -0.18x as of March 2026, meaning its operating cash flow of ₩-2.77 Billion could theoretically repay 0% of its total liabilities (₩15.35 Billion) in one year. Check SyntekaBio Inc (226330) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SyntekaBio Inc (2017–2025)
Cash flow-to-debt ratio of SyntekaBio Inc from 2017 to 2025. Historical debt coverage capacity for SyntekaBio Inc across 9 annual periods. Check how aggressively does SyntekaBio Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
SyntekaBio Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
SyntekaBio Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for SyntekaBio Inc. For the full cash flow conversion analysis, see 226330 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.72x | ₩-10.65 Billion | ₩14.76 Billion | ▼ -28.9% |
| 2024 | -0.56x | ₩-10.51 Billion | ₩18.77 Billion | ▼ -50.3% |
| 2023 | -0.37x | ₩-8.08 Billion | ₩21.69 Billion | ▼ -6.0% |
| 2022 | -0.35x | ₩-8.51 Billion | ₩24.23 Billion | ▼ -134.1% |
| 2021 | -0.15x | ₩-6.04 Billion | ₩40.25 Billion | ▲ +89.6% |
| 2020 | -1.44x | ₩-4.67 Billion | ₩3.24 Billion | ▲ +19.3% |
| 2019 | -1.79x | ₩-3.28 Billion | ₩1.84 Billion | ▼ -690.6% |
| 2018 | -0.23x | ₩-2.37 Billion | ₩10.47 Billion | ▲ +51.9% |
| 2017 | -0.47x | ₩-2.49 Billion | ₩5.29 Billion | — |